Last reviewed · How we verify
TDaP-IPV vaccine
TDaP-IPV is a combination vaccine that stimulates the immune system to produce antibodies against tetanus, diphtheria, pertussis, and poliovirus.
TDaP-IPV is a combination vaccine that stimulates the immune system to produce antibodies against tetanus, diphtheria, pertussis, and poliovirus. Used for Prevention of tetanus, diphtheria, pertussis, and poliomyelitis in infants and children.
At a glance
| Generic name | TDaP-IPV vaccine |
|---|---|
| Sponsor | Radboud University Medical Center |
| Drug class | combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated toxoids of tetanus and diphtheria, acellular pertussis antigens, and inactivated poliovirus particles. Upon administration, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory B cells against these four pathogens. This provides immunological protection against tetanus, diphtheria, whooping cough, and poliomyelitis.
Approved indications
- Prevention of tetanus, diphtheria, pertussis, and poliomyelitis in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
- Loss of appetite
Key clinical trials
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations (PHASE4)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Immunogenicity of a Combined Diphtheria-Tetanus-recombinant Acellular Pertussis (DTaP) Vaccine in Healthy Toddlers (PHASE2, PHASE3)
- Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TDaP-IPV vaccine CI brief — competitive landscape report
- TDaP-IPV vaccine updates RSS · CI watch RSS
- Radboud University Medical Center portfolio CI